Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

In this communication, we propose a dual-band Fabry-Perot (F-P) cavity antenna with a wideband low radar cross section (RCS) by integrating a Pancharatnam-Berry phase coding metasurface (PBPCM) and ...